Although endocrine-related gene expression has been previously associated with good response to aromatase inhibitors and high levels of ERBB2 with poor response, there is an overall lack of optimal biomarkers to pair with the optimal treatment for each patient within ER+/HER2+ BC. Here, ERBB2 is linked to breast cancer.